Summary The main objective of phase II clinical trials is to estimate treatment efficacy on a relatively small number of patients in order to decide whether the treatment ought to be studied in large-scale comparative trials. They 
To determine the number of patients required for a phase II trial, different multistage designs have been developed. The first design was proposed by Gehan in 1961 and is still being widely used (Gehan, 1961) , although rarely cited. It is a two-stage design which allows for the rapid rejection of an ineffective treatment at the end of the first stage, and provides an estimation of the success rate with a given precision, at the end of the second stage. Fleming (1982) and for precisions of 5% and 10%. These tables are also provided in a recent book (Machin et al., 1996) . The size of the second stage varies greatly, varying for instance, after the inclusion of nine patients, between 71 and 91 depending on the number of successes observed during the first stage, for a precision of 5%. For pl=0.20 and ft,=5%, which were the values used by Gehan in his original paper, one gets n1 = 14. This particular result, n, = 14, is often quoted without any mention of the underlying hypothesis, but with reference to Gehan's paper.
Gehan's design is different from the designs presented below because it considers the sample size problem from an estimation point of view, while controlling the risk ,B of rejecting an effective treatment. There is no need to specify a value Po of minimal efficacy, which would be used for controlling the probability a of accepting an ineffective treatment. The other designs presented here determine sample size and rejection regions, while controlling for both cx and ,B error rates. These designs do not consider the problem of estimation.
Fleming's designs Fleming (1982) 
Comparision of designs
We have compared the designs, using typical error rates of a=0.05 and f=0.10. The treatment was considered as not sufficiently effective if the true proportion of successes was less than or equal to po = 10%. If the true proportion of successes was greater than or equal to p, = 30%, the treatment was considered as worthy of study in a phase III trial. These proportions, po and p' are symmetrical around 20%, a success rate frequently used in phase II oncology trials which study one treatment.
In principle, Gehan's design cannot be compared with the other designs since it specifies the error rate ft' but does not specify the error rate a. In order to guarantee an overall # error rate of 10%, we have chosen a design which satisfies Gehan's constraint of ft' =5%. This leads to the inclusion of nine patients in the first step. The total number of patients equal to 35 has been selected according to Fleming's design (see below). This leads to an overall ft error of 9% for Pi = 30%. R is the cumulative number of successes at the end of stage k. 'Including the probability of termination at the end of stage 1.
reasonably close to 10%. If the treatment has a true efficacy of 10%, the average number of patients (AN) is 24.7 and the probability of early termination (PET) after the first stage is 69%. This PET is the sum of the probability of early termination with a correct conclusion of inefficacy (68%) and of the probability a, of early termination with a wrong conclusion of efficacy (1%). If the treatment has a true efficacy of 30%, the average number of patients is 25.7 and the probability of early termination after the first stage is 62%. This PET is the sum of the probability of early termination with a correct conclusion of efficacy (58%) and of the probability fl3 of early termination with a wrong conclusion of inefficacy (4%).
Comparing the different designs, one can seen that the maximal sample size varies from 33 for Simon's Minimax design to 45 patients for Ensign's design. The number of patients included in the first stage varies from nine for Gehan's and Ensign's designs to 22 for Simon's Minimax design.
After the first stage, Ensign's design, like Gehan's design, always stops with a conclusion of inefficacy if no successes are observed; the other designs stop with a conclusion of inefficacy if fewer than three successes are observed.
Under the hypothesis of inefficacy, Ensign's design and Simon's Optimum design have the largest overall probabilities of early termination of the trial (84% and 74%). Among the designs presented in Table I , Gehan's and Ensign's design have the smallest probability of early termination at the end of the first stage. In general, a larger probability of early termination corresponds to a smaller average sample size.
Under the hypothesis of efficacy, Fleming's design leads to the highest probability of early termination and to the smallest average sample size followed by Simon's Minimax design, Simon's Optimum design, Gehan's design and Ensign's design.
We have studied the robustness of the ranking of the five designs to variations of oa, /, po and Pi, considering all nine combinations of the selection of either o= 5%, ,B= 10%, or a=5%, /=5%, or a=10%, ,B=10%, and the selection of either p0= 10%, pi=30%, or po=20%, p,=40%, or po 30%, p, 50%. In general, under the hypothesis of inefficacy, Ensign's design had the largest overall probability of early termination, followed by Simon's Optimum design, Fleming's design and Simon's Minimax design; Gehan's design having the smallest probability of early termination. Under the hypothesis of efficacy, the largest probability of early termination was obtained with Fleming's design, followed by Ensign's design, Simon's Minimum and Simon's Optimum designs; Gehan's design corresponding to the smallest probability of early termination.
Literature review
We have analysed 3 -10 issues published between January and November 1995 of five journals: American Journal of Clinical Oncology, British Journal of Cancer, Cancer, European Journal of Cancer and Journal of Clinical Oncology, searching for chemotherapy trials in oncology that were either described as 'phase II' anywhere in the text, or had tumour response for main end point (these trials being sometimes described as 'pilot studies'). A total of 83 papers reporting phase II studies as defined above, were identified: 26 in the American Journal of Clinical Oncology, 18 in the European Journal of Cancer, 14 in the Journal of Clinical Oncology, 13 in Cancer and 12 in the British Journal of Cancer.
Out of these 83 papers, ten (12%) included at least some information on the statistical technique used: four reported using Gehan's design, one Fleming's design, two Simon's design, one an 'optimal restricted Bayes sampling', the last two specified po and the planned total number of patients, without specifying the number of stages, one specifying also the values of a, /3, and p,. The other 73 papers did not specify any of the following: name of statistical method, number of stages, oc, /3, po and p,. Among these 73 trials, the 11 in which zero response has been observed could be considered as having been conducted according to Gehan's design. With this extremely optimistic interpretation, the proportion of trials having used an identifiable statistical design rises to 25%.
Discussion
Gehan's design is simple and easy to understand. It (1) a definition of the end points defining success: (2) the name of the design used and a reference to a published description of the method: (3) the success rate po below which one wants to reject the treatment: (4) .. the probability of a conclusion in favour of efficacy when the rate of success is po or less: (5) The success rate Pi above which one wants to accept the treatment:
(6) /3. the probability of a conclusion of inefficacy when the level of efficacy is above P, Publications reporting the results of a phase II trial should include the same information. It should also present the observed success rate with its confidence interval.
